{
    "title": "UPDATE 1-Merck sees 2022 sales up nearly 20%, mostly on new COVID pill",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10473371/Merck-sees-2022-sales-nearly-20--new-COVID-pill.html",
    "date": "2022-02-03",
    "keywords": [
        "drug",
        "molnupiravir",
        "year",
        "pill",
        "merck",
        "litchfield",
        "supply",
        "treatment",
        "trial",
        "development",
        "business",
        "erman",
        "covid19",
        "quarter",
        "end",
        "efficacy",
        "company",
        "co",
        "thursday",
        "percent",
        "drugmaker",
        "ridgeback",
        "officer",
        "caroline",
        "interview",
        "weve",
        "product",
        "game",
        "changer",
        "pfizer",
        "inc",
        "term",
        "choice",
        "covid",
        "atrisk",
        "success",
        "patient",
        "placebo",
        "group",
        "death",
        "rate",
        "access",
        "mortality",
        "dean",
        "li",
        "head",
        "research",
        "conference",
        "call",
        "government",
        "week",
        "course",
        "option",
        "order",
        "growth",
        "blockbuster",
        "cancer",
        "keytruda",
        "papillomavirus",
        "hpv",
        "vaccine",
        "gardasil",
        "revenue",
        "morning",
        "trading",
        "cash",
        "windfall",
        "goal",
        "level",
        "share",
        "reporting",
        "richard",
        "pullin",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}